Department of Plastic, Reconstructive and Hand Surgery, Peninsula Health, Frankston, VIC, Australia.
Peninsula Clinical School, Central Clinical School at Monash University, The Alfred Centre, Melbourne, VIC, Australia.
J Hand Surg Asian Pac Vol. 2020 Dec;25(4):453-461. doi: 10.1142/S2424835520500502.
Management of Dupuytren Disease is variable, and influenced by multiple factors including location, extent of disease, surgical preference and familiarity with different treatment techniques. The objective of this study was to determine current Dupuytren Disease management trends in Australia. A questionnaire was sent through The Australian Hand Surgery Society to all members. In addition to demographic data, indications and preferences for different management interventions were surveyed on location of disease, age and activity level of the patient. 99 (48%) of the Australian Hand Surgery Society members completed the survey. Respondents were primarily Orthopaedic (50%) or Plastic (49%) Surgeons, and most worked in private (99%) and public (71%) practice. Surgeon's believed that Tubiana's treatment goals to correct deformity was the most important (60%) and to shorten post-operative recovery (60%) was the least important. Only 42% of respondents perform needle aponeurotomy for Dupuytren Disease. In contrast 70% of respondents perform collagenase injections, with manipulation most commonly undertaken on the second day (46%) and skin tears (52%) the most common complication. Seventy-five percent of the respondents feel there is sufficient evidence to support the treatment of Dupuytren disease with collagenase injections. Ninety nine percent of all respondents perform fasciectomes for Dupuytren Disease, with Limited (without graft) (76%) the most routine performed. Several procedural options for the treatment of Dupuytren Disease exist within Australia. This study shows current Australian practice trends and highlights the increasing use of collagenase.
迪普屈恩病的治疗方法多种多样,受到多种因素的影响,包括病变位置、疾病严重程度、手术偏好以及对不同治疗技术的熟悉程度。本研究旨在确定澳大利亚目前迪普屈恩病的治疗趋势。通过澳大利亚手部外科学会向所有会员发送了一份问卷。除了人口统计学数据外,还调查了不同管理干预措施的适应证和偏好,包括病变位置、患者年龄和活动水平。澳大利亚手部外科学会的 99 名(48%)成员完成了调查。受访者主要是骨科(50%)或整形外科(49%)医生,大多数在私人(99%)和公共(71%)医疗机构工作。外科医生认为,图比亚纳的治疗目标是纠正畸形(60%),缩短术后恢复期(60%)是最不重要的。只有 42%的受访者对迪普屈恩病进行针刀切开术。相比之下,70%的受访者进行胶原酶注射,最常见的操作是在第 2 天(46%)进行,皮肤撕裂(52%)是最常见的并发症。75%的受访者认为有足够的证据支持用胶原酶注射治疗迪普屈恩病。所有受访者的 99%都对迪普屈恩病施行筋膜切除术,其中有限(不移植)(76%)是最常见的手术。澳大利亚有几种治疗迪普屈恩病的手术选择。本研究显示了当前澳大利亚的实践趋势,并强调了胶原酶的使用日益增多。